EPISODE · Feb 28, 2026 · 9 MIN
#108 $RGNX REGENXBIO Gene Therapy Breakthrough or Clinical Hold Shock
from SueWallSt · host SueWallSt
In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventeen percent stock drop that followed. This deep dive is for biotech investors, gene therapy traders, and anyone following FDA risk, clinical trial safety, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventeen percent stock drop that followed. This deep dive is for biotech investors, gene therapy traders, and anyone following FDA risk, clinical trial safety, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#108 $RGNX REGENXBIO Gene Therapy Breakthrough or Clinical Hold Shock
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.